Cyclopentanone

Cyclopentanone

SCHEMBL57700

O=C1CCCC1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclopentanone SCHEMBL1332555 1.00
Cyclopentanone SCHEMBL27612284 1.00
SCHEMBL1262325 1.00 TRIM24 (1.00)
Cyclopentanone SCHEMBL2797344 1.00 TRIM24 (1.00)
Cyclopentanone SCHEMBL19364 1.00
SCHEMBL25380098 0.95 TRIM24 (1.00)
Cyclopentanone SCHEMBL3109551 0.95
Cyclopentanone SCHEMBL11529014 0.95 TRIM24 (0.91)
Cyclopentanone SCHEMBL3693524 0.95
SCHEMBL112034 0.95 TRIM24 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115093396-A Pyridine ether compound containing pyrimidinamine and preparation method and application thereof 湖南化工研究院有限公司 2022-09-23 CN claimed
CN-113754639-A Pyridylether compound containing pyrimidinamine and preparation and application thereof 湖南化工研究院有限公司 2021-12-07 CN claimed
CN-113754637-A Pyridine ether compound containing pyrimidinamine 湖南化工研究院有限公司 2021-12-07 CN claimed
CN-115093396-B Pyridinylether compound containing pyrimidamine and preparation method and application thereof 湖南化工研究院有限公司 2024-03-29 CN disclosed
US-11844822-B2 Solid formulation and method for preventing or reducing coloration thereof ELOBIX AB (SE) 2023-12-19 US disclosed
US-20230330176-A1 PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER ALBIREO AB (SE) 2023-10-19 US disclosed
US-11732006-B2 IBAT inhibitors for the treatment of liver diseases ALBIREO AB (SE) 2023-08-22 US disclosed
US-20230165974-A1 COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICALLY ACTIVE AGENTS MEDIMMUNE, LLC 2023-06-01 US disclosed
US-20230109432-A1 IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES ALBIREO AB (SE) 2023-04-06 US disclosed
EP-4143205-A1 COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICALLY ACTIVE AGENTS Medimmune, LLC (US) 2023-03-08 EP disclosed
CN-115461357-A Compositions and methods for delivering pharmaceutically active agents 免疫医疗有限责任公司 2022-12-09 CN disclosed
CN-1416425-A 1,5-bemzothiazepines and their use as hypolipidaemics ASTRAZENECA AB (SE) 2003-05-07 CN disclosed
WO-2003022830-A1 BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBITORS ASTRAZENECA AB (SE) 2003-03-20 WO disclosed
WO-2003022286-A1 BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA ASTRAZENECA AB (SE) 2003-03-20 WO disclosed
WO-2003022825-A1 BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA ASTRAZENECA AB (SE) 2003-03-20 WO disclosed
WO-2003020710-A1 BENZOTHIAZEPINE DERIVATIVES ASTRAZENECA AB (SE) 2003-03-13 WO disclosed
EP-1263747-A1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS AstraZeneca AB (SE) 2002-12-11 EP disclosed
WO-2002051806-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2002-07-04 WO disclosed
WO-2002050051-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-06-27 WO disclosed
WO-2001066533-A1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS ASTRAZENECA AB (SE) 2001-09-13 WO disclosed